PET Imaging of Brain Peripheral Benzodiazepine Receptors
NCT00283920 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2017-07-02
Summary
This study will use positron emission tomography (PET) and magnetic resonance imaging (MRI) to measure peripheral benzodiazepine receptors (PBRs) in the brain. PBRs were initially found in peripheral organs such as kidneys, endocrine glands and lungs, but later studies identified PBRs in the CNS. PBRs can be a marker to detect nervous system inflammation. Development of a test to image PBRs may improve the management of brain disorders such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and others in which inflammation is involved in progression of the disease.
Healthy volunteers from 18 to 40 years old may be eligible for this study. Candidates are screened with tests that may include some or all of the following: diagnostic interview; ratings of mood, anxiety, functioning, and other parameters; neuropsychological testing; physical examination; electrocardiogram; blood and urine tests; and personal, social and family histories.
Participants undergo the following procedures:
* Evaluation: Subjects provide a medical history, including detailed questions about their psychological health, and have a physical examination and blood and urine tests.
* PET scanning: PET uses small amounts of a radioactive chemical called a tracer that "labels" active areas of the brain. The tracer used in this study is \[11C\]PBR28. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the head still during the scan so the images will be clear. A brief scan is done just before the radioactive tracer is injected to provide measures of the brain that will help to precisely calculate information from subsequent scans. After the tracer is injected through a catheter (plastic tube) placed in the arm, pictures are taken for 2 to 3 hours, during which the subject lies still on the scanner bed. Subjects return to the clinic the following day for more blood and urine sample collections.
* MRI: The MRI scan is done within 1 year of the PET scan (either before or after the PET). MRI uses magnetic fields and radio waves to produce images of the brain. The patient lies on a table that is moved into the scanner (a narrow cylinder), wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. He or she can communicate with the staff at all times during the procedure.
Conditions
- Healthy Volunteer
Interventions
- DRUG
-
[(11)C] PBR28
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-01-26
- Completion
- 2007-10-02
Countries
- United States
Study Locations
More Related Trials
-
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis
NCT00547976 ·Status: COMPLETED ·Phase: PHASE1
-
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
NCT04057807 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)
NCT00459693 ·Status: TERMINATED ·Phase: NA
-
Imaging Inflammation in Alzheimer's Disease
NCT02831283 ·Status: COMPLETED ·Phase: PHASE2
-
PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2
NCT00598286 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
NCT03545789 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209 ·Status: TERMINATED ·Phase: PHASE1
-
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
NCT00250172 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP
NCT00598390 ·Status: COMPLETED ·Phase: PHASE1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01209156 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873 ·Status: RECRUITING ·Phase: PHASE1
-
Translocator Protein and Inflammation After Traumatic Brain Injury
NCT01547780 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PET Study of the Nicotinic System in Epilepsy
NCT03268369 ·Status: COMPLETED ·Phase: NA
-
Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy
NCT02003183 ·Status: COMPLETED
-
Brain Blood Flow Studies of Language and Memory
NCT00001288 ·Status: COMPLETED
-
PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
NCT06920628 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
NCT03876002 ·Status: COMPLETED ·Phase: PHASE1
-
Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200 ·Status: COMPLETED
-
Reproducibility of the 11C-PBR28 PET Signal
NCT02086240 ·Status: WITHDRAWN ·Phase: NA
-
Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.
NCT03514524 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
PET Scan in Patients With Neurocardiologic Disorders
NCT00001418 ·Status: COMPLETED
-
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
NCT06289582 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
NCT06299410 ·Status: RECRUITING ·Phase: PHASE1
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1